Control of cattle mange in southern africa using ivermectin

Seven trials including 768 cattle were conducted in South Africa and Namibia to evaluate the efficacy of the systemic parasiticide ivermectin when administered subcutaneously at a dose rate of 200 micrograms/kg against sarcoptic (Sarcoptes scabiei var. bovis), chorioptic (Chorioptes bovis) and psoroptic (Psoroptes ovis var. bovis) mange mites. The efficacy of a single treatment against Psoroptes and Sarcoptes was greater than against Chorioptes. There was marked clinical cure in all treated cases with loss of crusts and hair regrowth. The number of cases of psoroptic mange in two large herds, of which 42.4% of 724 animals were clinically affected prior to mass treatment, was reduced by 99.3% following a single subcutaneous treatment with ivermectin; a single animal from which mites were recovered may not have been treated. The apparent prevalence and prospects for control and eradication of cattle mange in South Africa and Namibia are discussed.     

Efficacy of moxidectin against sarcoptic mange and effects on milk yield of ewes and growth of lambs

Forty-eight dairy ewes and 45 lambs naturally infested with sarcoptic mange, were divided into three equal groups and treated with moxidectin 1% inj. sol. at a dose rate of 0.2 mg moxidectin kg(-1) bodyweight once or twice ten days apart. During the study, the skin lesions were scored and the number of mites recovered in facial skin scrapings from the animals were recorded. Moxidectin was found to be effective against ovine sarcoptic mange, when given twice; the percentage reduction of mites was 100% (p < 0.0001) and the skin lesions disappeared completely (p = 0.0001). In sheep treated once only, the percentage reduction of mites varied from 75% to 92%. Treated ewes produced up to 22.4% more milk than the infested ones (p = 0.0001). Treated lambs had up to 15% greater final weight and up to 23.7% more growth than infested controls (p = 0.0001). It is concluded that two injections of moxidectin 1% inj. sol. at a dose rate of 0.2 mg kg(-1) bodyweight, given ten days apart, were effective against ovine sarcoptic mange. Furthermore, it is considered that sarcoptic mange adversely affects the production of the infested animals.     

Effects of sarcoptic mange and its control with oil of Cedrus deodara, Pongamia glabra, Jatropha curcas and benzyl benzoate, both with and without ascorbic acid on growing sheep: epidemiology; assessment of clinical, haematological, cell-mediated humoral immune responses and pathology

The aim of this study was to evaluate the therapeutic efficacy of commonly used acaricidal drugs in India and also to assess the effect of ascorbic acid (AA) as adjunct therapy in 72 growing sheep with sarcoptic mange, aged 5-6 months and weighing 20.4-31.7 kg. Eight replicates of nine animals were formed based on sex, and day 0 body weight. Another set of 12 healthy sheep (5-6 months old) constituted the healthy control group. Drugs were applied locally on the affected parts daily and recovery changes in skin lesions were observed at the time of every application. L-Ascorbic acid was administered intramuscularly. Skin scrapings were collected daily from each group and examined for the presence of mites. Blood samples from each group were collected and analysed for total erythrocytes, leucocytes, haematocrit, haemoglobin and lymphocytes on 0, 14th and 28th day post-treatment (PT). Cell-mediated (CMI) and humoral immune (HI) responses were assessed on 0 and 28 days PT. Within groups treated with the drug alone, recovery in oil of Jatropha curcas group was faster and lesions were free from mites after the eighth application. For each drug, the recovery was faster with AA as an adjunct therapy when compared with the group treated with the drug alone. Within all groups, recovery in oil of J. curcas plus ascorbic acid (OJC-AA) group was fastest and the lesions were mite-free after three applications. The overall mean values were higher for all haematological parameters in OJC-AA group. Recovery with respect to suppressed CMI and HI responses during infection was also faster in this group. Gross and microscopic pathological studies revealed a marked adverse effect of infection on skin, kidney, spleen and liver. The OJC-AA group indicated faster recovery. It is concluded from this study that oil of J. curcas was found more efficacious in controlling sarcoptic mange in sheep and AA might be beneficial as adjunct in case of sarcoptic mange to get quick recovery with lesser applications of main therapy. However, the pharmacology of AA with reference to health of skin needs to be investigated.     

Notoedric mange in two free-ranging North American racoons (Procyon lotor) in Japan

Mange was diagnosed in two North American racoons (Procyon lotor) at Kamakura City in Kanagawa Prefecture, Japan. The mites were identified morphologically as Notoedres cati. Mite infestation affected the skin over the extremities and tail, and was characterized by moderate alopecia and erythematous dermatosis. Histopathologically, the affected skin showed marked epidermal hyperplasia and mites located within the parakeratotic stratum corneum. A slight dermal inflammatory response consisting principally of mononuclear cells was observed. N. cati mites were demonstrated in their tunnels using scanning electron microscopy (SEM). This is the first report of notoedric mange in racoons.     

Comparative therapeutic effect of moxidectin,doramectin and ivermectin on psoroptes mites infestation in buffalo (<Emphasis Type="Italic">Bubalus bubalis</Emphasis>)

The aim of the present study was to carry out comparative therapeutic effect of moxidectin pour on, doramectin and ivermectin on psoroptes infestation in buffalo. A total of 318 buffalo in 77 small scale herds suspected to have mange mites were examined clinically and parasitologically. Fifty-three (16.66%) buffalo in 25 herds were recorded to be infested; 51 (16.35%) with psoroptic mites, and two (0.31%) with chorioptic mites. Buffalo with psoroptic mites were randomly allocated into three groups (17 buffalo each). First group was treated with moxidectin pour on at a dose rate of 0.5 mg kg^-1. The second group received doramectin (200 μg kg^-1 twice subcutaneously, 14 days apart). The third group received ivermectin (200 μg kg^-1 twice subcutaneously, 14 days apart). Adjunct to each drug, deltamethrin was applied to the surrounding environment twice at a two week interval. Treatment outcomes of 51 buffalo with psoroptic mites showed that moxidectin pour on and doramectin had a significant higher effect on mite count reduction (MANOVA, P < 0.01; Walks^, Lambda, P < 0.01) and clinical sum scores (MANOVA, P < 0.05; Walks^, Lambda, P < 0.05) compared with injectible ivermectin. On clinical level, the number of clinically recovered buffalo in moxidectin and doramectin treated groups was significantly (P < 0.05) higher than that of ivermectin treated group. The result of the present study indicated that psoroptic mites are the main cause of mange in buffalo in Lower Egypt. This is the first report that describes the effect of moxidectin in buffalo. Moxidectin is a good alternative and easily applied drug for treatment of psoroptes infestation in buffalo.     

Effect of ivermectin on the ear mange mite, Psoroptes cuniculi, of rabbits

Rabbits, naturally infected with ear mange mite, Psoroptes cuniculi, were injected subcutaneously with a single dose of ivermectin at 200 micrograms or 400 micrograms/kg of body weight. The effect of the drug was evaluated clinically and parasitologically over 4 weeks. The animals in both groups became negative for mites 6 days after treatment and remained so until the end of trial. The ear lesions disappeared in both groups. However, the regression of lesions was faster in rabbits administered 400 micrograms/kg of ivermectin.     

Eprinomectin treatment of psoroptic mange in hunter/jumper and dressage horses: a prospective, randomized, double-blinded, placebo-controlled clinical trial

The purpose of this prospective, double-blinded, placebo-controlled clinical trial was to investigate the efficacy of topical eprinomectin for the treatment of psoroptic mange infestation in horses. 24 privately owned hunter/jumper and dressage horses were diagnosed with psoroptic mange infestation based on physical findings and skin scraping results were enrolled and randomly assigned to either topical eprinomectin pour-on solution (at a dose of 500mug/kg body weight weekly once for four applications) treatment group or a placebo group (purified water). Clinical evaluations and skin scrapings were done by the same veterinary investigator at the beginning, during and at the end of the treatment. Both owners and veterinary investigator were blinded to the allocation to the groups. The efficacy of eprinomectin was assessed both clinically and parasitologically by the presence or absence of viable mites. Horses were scraped for psoroptic mites on days 7, 14, 21, 28 and 40 for follow-up. Fisher's exact test was used to assess differences between the eprinomectin treatment and placebo in the number of horses without mites (cure rates) on each assessment date. It was found that significantly fewer eprinomectin treated horses had P. equi mites detected on skin scrapings (p<0.01) than the placebo group. In conclusion, eprinomectin was effective and safe therapy against natural infestations of P. equi in the horses included in this study.     

Haematological and immunological response of unrestrained cattle to Psoroptes ovis, the sheep scab mite

Cows were infected twice with 600 and 500 nymphs and adults of a bovine strain of Psoroptes ovis with a nine-week interval. The haematological response and the non-specific mitogen- and antigen-induced responsiveness of the peripheral blood lymphocytes of the animals was followed. Dermal reactivity to P ovis antigen injection was studied five weeks after reinfection. After the first infection with 600 mites none of the infected animals developed clinical psoroptic mange but a leucocytosis developed, contributed to primarily by an eosinophilia and by a slight lymphocytosis. Antigen-induced lymphocyte blastogenesis was used to measure the antigen-sensitive cell population in peripheral blood and this population showed a maximum increase 10 days after infection; however, antigen-sensitive cells remained above normal levels until reinfection. Upon challenge infection with 500 mites the infected animals showed an immediate hypersensitivity type reaction with a marked pruritus, scratching and exudation. Thereafter the lesions healed rapidly and none of the animals developed clinical mange. This clinical reaction was accompanied by a secondary eosinophilia but no change was apparent in the other blood elements. A marked increase in the blastogenic response of the peripheral blood lymphocytes was also apparent and this peaked three weeks after challenge. Following the intradermal injection of P ovis antigen there was an immediate swelling of the injection site in all infected and control animals and skin thickness was maximal one hour after injection. Thereafter there was a clear distinction in dermal reactions between P ovis infected and control animals; after 48 hours reactions were not seen in the control animals while marked dermal reactions were still present in the P ovis infected group.     

Comparative evaluation of two ivermectin injectable formulations against psoroptic mange in feedlot cattle

A study was carried out to compare the efficacy of two injectable formulations of ivermectin, Ivomec,(1) Merial (IVM reference) and Ivogell,(2) Intervet (IVM generic) in the treatment of psoroptic mange (Psoroptes ovis) in Charollais feedlot cattle. A total of 22 animals were ranked in order of the severity of mange and allocated to 11 replicates of 2 animals each. Within each replicate, one animal was randomly allocated to IVM reference product treatment (Group 1) and one to IVM generic (Group 2). Animals were treated on Day 0 and on Day 8 at the recommended dosage of 200 microg ivermectin/kg bodyweight. The pharmacokinetics profiles (pK) of both IVM formulations were evaluated in plasma samples taken from 6 cattle randomly chosen per group on Day 0, before treatment, and then at 6, 12, 24 hours and daily from Day 2 to Day 7 after the treatment on Day 0. Additionally, the severity of mange lesions was assessed and mites were counted in skin scrapings on Days 0, 8, 15 and 25. Animals were weighed on Day 0 and 25 and body weight and average daily gains (ADG) were evaluated. No statistical differences were found between the cattle of the two groups in any pK parameters, although the mean IVM plasma concentrations in cattle treated with the IVM reference product were consistently higher than those found in cattle treated with the generic compound. By Day 25, all animals in Group 1 had recovered clinically and parasitologically from psoroptic mange while cattle from Group 2 still had mange lesions and, in two animals, living mites were found in the skin scrapings; these differences were significant (P<0.001). The mean body weight of the two groups was significantly different on Day 25 (P<0.01) when animals in Group 1 weighed 20 kg more than those in Group 2. In conclusion, despite similarities in their pharmacokinetic profiles and formulations, the clinical efficacy of the two injectable formulations of IVM differed significantly in their therapeutic efficacy against psoroptic mange in feedlot cattle up to 25 days after treatment: this difference in response was reflected in an incomplete clinical and parasitological response in Group 2 and a slower growth rate.     

Risk factors of infestation by Psoroptes spp. mites in buffalo (Bubalus bubalis) at smallholder farms in the Nile Delta region, Egypt

The aim of the present study was to explore the prevalence and potential risk factors associated with infestation by Psoroptes spp. mites in buffalo at smallholder farms in the Nile Delta region, Egypt. A total of 318 out of 1234 buffalo in 77 small scale herds were examined. The age of buffalo varied from three months to seven years. In all, 53 (16.66%) buffalo were recorded to be infested; 51 (16.35%) with Psoroptes spp. mites and two cases (0.31%) with Chorioptes spp. mites. Multivariate logistic regression was performed for significant risk factors at univariate analysis on both animal and herd level. The results of multivariate analysis showed that, on the animal level, the prevalence was affected by animal age (P?<?0.01; OR: 0.71; CI 95%: 0.441–1.11), season (P?<?0.01; OR: 1.20; CI 95%:0.541–1.15), indoor management (P?<?0.001; OR: 6.625; CI 95%:2.489 –17.631) and rearing with other animals (P?<?0.01; OR: 2.22; CI 95%:1.340 –7.132). However, on the herd level, the prevalence was affected by indoor rearing (P?<?0.05; OR: 22.4; CI 95%:2.75–16.431), mixed rearing with other animal species (P?<?0.05; OR: 4.5; CI 95%:1.66–7.941), and season (P?<?0.01; OR: 2.3; CI 95%:0.575–2.426). Clinically, mild skin lesions with mild pruritis were significantly prevalent in buffalo with the infestation by Psoroptes spp. mites (P?<?0.001), where 33/51 cases showed mild lesions. Also, psoroptic mites had significant association with inappitence (P?<?0.001). The result of the present study indicates that Psoroptes spp. mites are the most prevalent in buffalo in the Nile Delta Region, Egypt. Moreover, recognition of risk factors associated with mange mites in buffalo may enable the practitioner to establish the most appropriate control measures.     

Outbreak of sarcoptic mange in alpacas (Vicugna pacos) and control with repeated subcutaneous ivermectin injections

An outbreak of sarcoptic mange was investigated in an alpaca herd. Clinical disease occurred 2 months after the introduction of four alpacas with dry seborrhoeic skin lesions, the cause of which was not investigated. Initially a group of females was affected, despite repeated topical treatment with ivermectin at a dose of 0.5 mg/kg bodyweight. One female died and post-mortem examination indicated sarcoptic mange as the cause of death. Infection with Sarcoptes scabiei was also demonstrated on microscopic examination of skin scrapes taken from clinically affected cohorts. Later in the outbreak, a separate group of male alpacas was also affected. Treatment using subcutaneous ivermectin injections at a dose of 0.2 mg/kg, administered at 14-day intervals, was evaluated. During this course of treatment, another female died. A successful response in the other alpacas was eventually reached following 12 treatments of the female group and 8 treatments of the male group.     

Willingness to pay for cattle and buffalo insurance: an analysis of dairy farmers in central India

In India, insurance market especially in agricultural sector is usually underdeveloped. The idea of livestock insurance emerged in India before three decades, yet, it has not operated in a significant way till date. It is well noted that livestock insurance scheme is the relevant strategy in managing different risks related to livestock farming but very little attention has been paid to address the livestock insurance needs of the dairy farmers. This study, therefore, addresses the basic question that how many people and to what extent they are willing to pay for livestock insurance and determine the main factors which influence insurance participation of dairy farmers. The data was collected from Gorakhpur district of Uttar Pradesh in India with a sample survey of 120 cattle and buffalo farmers. For eliciting willingness to pay, a contingent valuation scenario was presented to dairy animal owners in the group of five to six. A logit discrete binary regression model was used to know the factors influencing adoption of livestock insurance. The results suggest that most of the farmers were willing to participate in cattle and buffalo insurance. The amount of premium varies across different breeds of dairy animals. The low level of education of many dairy farmers have negatively influenced the decision to purchase livestock insurance. Farmers having more experience in rearing dairy animals are more likely to be willing to pay for cattle and buffalo insurance.     

米尔贝肟对自然感染疥螨病犬的治疗效果

为了评价米尔贝肟对临床自然感染疥螨犬的治疗效果,选用自然感染疥螨犬65例,随机选择5条服用伊维菌素,另外60条随机分为3组,分别服用高剂量(2g/kg体重)、中剂量(1g/kg体重)、低剂量(0.5g/kg体重)的米尔贝肟。给药后2、14、28、42d和56d,刮取皮屑,检查螨虫和虫卵,同时观察临床症状。试验结束时米尔贝肟高剂量组、伊维菌素组的无螨虫犬的比例和螨虫的下降率均为100%,临床症状如红疹、结痂、过度角化等现象均消失,所有动物毛发都开始大范围重生;米尔贝肟中、低剂量组结果稍差。米尔贝肟按2g/kg体重剂量,每周1次,连续用药3周,给药对自然感染疥螨病犬有很好的治疗效果。     

Clinical and therapeutic studies on mange in horses

At Kafr El-Sheikh province, Egypt, out of 117 examined drafting horses, mites were detected in 20 (17.09%) horses. The recovered mites were 14 Chorioptes, four Psoroptes and two Sarcoptes whereas mites were not detected in four cases clinically showed typical mange lesions. Interestingly, neither the age nor the sex of the examined horses had a clear influence on the prevalence of the infection. Clinical signs observed in mange infested horses were in the form of irregular skin lesions, severe itching and sometimes biting of affected skin areas and decrease feed consumption. The skin lesions mainly start as erythematous area followed by developing of papules and crust formation. Skin scratches as a result of traumatized lesions usually occurred. Hair was lost on the affected parts developing irregular alopecic areas. Distribution of the lesions was varied according to the type of mite. Chorioptic mite was detected in para-anal fold, distal portion of legs and tail lesions, Psoroptic mite was detected in withers, mane, shoulder and flank lesions whereas Sarcoptic mite was isolated mainly from lesions on the head and neck. Complete clinical and parasitological cure for mite infestation were obtained within 2 weeks in both moxidectin and ivermectin treated groups with 100% recovery rate. Our results indicated that moxidectin oral gel is effective and good alternative for the treatment of chorioptic mange in horse to avoid drug resistance that may develop as a result of the intensive use of ivermectin alone for long periods.     

FC-44 The therapeutic effect of selamectin and ivermectin regimens in canine sarcoptic mange

Worldwide, sarcoptic mange in cats is seldom reported, and then only in sporadic individual cases. We describe an epidemic in a household with a dog and 25 cats. From September 2002, the dog was repeatedly treated with ivermectin for sarcoptic mange. The diagnosis was confirmed by skin scrapings. Fifteen months later, cats from the same household were diagnosed with severe sarcoptic mange. Twenty-one of the cats were euthanized and necropsies were performed. Skin samples were taken from all cats from different body sites for histology, and skin scrapings were examined for ectoparasites. Samples for bacterial and dermatophyte culture were taken from six cats. Smears for cytology were made from lesions on four cats with severe mange. Sera from 21 cats and the dog were analysed for specific antibodies to Sarcoptes scabiei . Molecular characterizations of six individual mites were done. Large numbers of S. scabiei were isolated from the infected skin of most of the cats. Two-thirds of the cats showed skin lesions compatible with chronic sarcoptic mange. Macroscopically, internal organs exhibited no obvious pathology. Yeast organisms and coccoid bacteria were found in the smears; penicillinase-negative Staphylococcus aureus was isolated from all samples and Malassezia pachydermatis was identified from four cats. Sarcoptes scabiei was seen histologically in all cats showing chronic skin lesions. No other ectoparasites were found. All analysed cats had specific antibodies against S. scabiei . Twenty-one cats tested negatively for FeLV and FIV. The mites had DNA sequences identical to S. scabiei from naturally infected dogs and Swedish wildlife.
Funding: Self-funded.     

Udder cleft dermatitis and sarcoptic mange in a dairy herd

OBJECTIVE: To determine prevalence of udder cleft dermatitis in a dairy herd that was experiencing an outbreak of sarcoptic mange. DESIGN: Clinical survey. ANIMALS: 1,597 Holstein cows and late-gestation heifers. PROCEDURE: Animals were examined for udder cleft dermatitis and for skin lesions consistent with sarcoptic or chorioptic mange. Skin scrapings were collected from 56 cows and examined for ectoparasites. The herd was revisited 1 year later, and prevalences of udder cleft dermatitis and lesions consistent with mange were determined in 506 cows. RESULTS: Of the 1,597 cattle examined, 280 (18%) had udder cleft dermatitis, and 1,397 (87.5%) had lesions consistent with mange. In 43 of 56 (77%) cows, skin scrapings revealed Sarcoptes mites. Udder cleft dermatitis was significantly more common in older than in younger cows. In first-lactation cows, udder cleft dermatitis was less common during the first 4 months of lactation than in the later stages of lactation, but udder cleft dermatitis was identified in cows in all stages of lactation and in cows that were not lactating. The herd was treated with eprinomectin to control mites, and prevalence of lesions consistent with mange 1 year later was only 2.8%. However, prevalence of udder cleft dermatitis was still 12%. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that cows in any stage of lactation and cows that are not lactating can have udder cleft dermatitis but that lesions are more common in older cows. Control of sarcoptic mange was accompanied by a moderate reduction in the prevalence of udder cleft dermatitis but did not eliminate the condition.     

Notoedric mange in free-ranging masked palm civets (Paguma larvata) in Japan

Fifty-one masked palm civets (Paguma larvata) were trapped as part of a nuisance wildlife control programme between July 2001 and August 2002 in Fujisawa City, Kanagawa Prefecture, Japan. Eleven civets had characteristic mange lesions with marked alopecia and crusts, caused by the burrowing epidermal mite Notoedres cati. The diagnosis was confirmed by histology and examination of mites obtained from skin scrapings of affected civets. Histopathology of lesions demonstrated moderate hyperplastic epidermis, parakeratosis and acanthosis. Occasionally microvascular angiogenesis was observed in the epidermis. Tunnels were excavated in the hair follicles, reaching the hair roots. The tunnels were located between the hair shaft and the inner root sheath. Female mites, eggs and nymphs were demonstrated in their tunnels using scanning electron microscopy.     

Clinical effects of ivermectin in the treatment of Sarcoptes scabiei var canis in farm foxes

The efficacy of ivermectin against natural infection of the mange mite Sarcoptes scabiei var canis in foxes was evaluated. The investigations consisted of two field studies and one controlled study. In experiment 1, ivermectin was given as a single subcutaneous dose at 200 micrograms/kg in six foxes. In experiment 2, was one group, consisting of five animals, administered 200 micrograms ivermectin/kg s.c. twice with an interval of 35 days. Group two, consisting of four animals, was given one subcutaneous injection of 400 micrograms ivermectin/kg. In experiment 3, ten foxes were given 1 ml 0.2% Eqvalen s.c. (i.e. 340-440 micrograms ivermectin/kg). A control group of ten animals was not medicated. Before and after treatment a clinical evaluation and skin scraping for microscopic examination was carried out in all three experiments. The results indicated that ivermectin was a good alternative in the therapy of the Sarcoptes mange in foxes by moderate mite infection. A progressive clinical improvement of the mange lesions was evident in the treated foxes. Mites were not detected in skinscraping, except in one animal in experiment 3. It was concluded that ivermectin should be administered, in an initial dose of 400 micrograms/kg and a repeated dose of 200 micrograms/kg 2-3 weeks after the first treatment.     

P-23 Clinical and epidemiological characteristics of 153 cases of Sarcoptic acariosis in dogs

A randomized and controlled field study was performed in canine patients to evaluate the efficacy of selamectin in the treatment of naturally occurring Sarcoptes scabiei and Otodectes cynotis infestations in dogs. A total of 227 dogs from six veterinary practices in South Korea were included. Dogs were randomly assigned to treatment with selamectin or a positive-control product. Selamectin was administered as a unit dose providing a minimum of 6 mg/kg in a topical preparation applied to the skin in a single spot on days 0 and 30 [ S. scabiei ( n =  113) and O. cynotis ( n =  114)]. The presence of parasites was assessed before treatment and at 14, 30 and 60 days after the initiation of treatment. The animals were evaluated clinically at each assessment period. Based on skin scrapings, the efficacy of selamectin against S. scabiei infestations on dogs was >95% by day 30, and 100% by day 60. Against O. cynotis , selamectin eliminated mites in 100% of dogs by day 60. However, clinical signs of pruritus, erythema, scale, and crusted papules did not diminish concomittantly with resolution of S. scabiei in skin scrapings. The positive-control products achieved similar results. Therefore, selamectin was safe and effective against sarcoptic mange and ear mites in dogs.
Funding: Pfizer Animal Health.     

Sarcoptic mange in captive maras: the first known outbreak and complete recovery with colony-wide acaricide treatment

Among 16 maras housed as a colony at a zoo, 2 initially showed generalized dermal lesions on the legs, head and abdomen. Approximately 1 month later, following completion of therapy with amitraz, 6 maras in the same colony, including the 2 previously diseased animals, showed dermal lesions with severe alopecia and crusting. Sarcoptic mange was diagnosed on skin scrapings on the basis of morphological criteria. The mites were highly mobile and abundant in all cases, and no other causative agents were detected. Colony-wide treatment with ivermectin and prednisolone was administered weekly for a total of 4 treatments. After therapy was completed in all cohabitants, follow-up scrapings were negative for Sarcoptes scabiei. This report describes the first known outbreak of sarcoptic mange in captive maras and successful treatment with acaricides.